Remote Patient Monitoring MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy ComponentBy ApplicationBy End UserBy Connectivity TechnologyBy WearabilityBy Deployment ModeBy Care ModelBy Patient Age GroupBy Sales Channel

Remote patient monitoring covers the devices, software and services that collect physiological data from a patient outside a clinical facility and send it to a care team for review and action. Products include connected vital signs, glucose, cardiac, respiratory and other monitors, the platforms that gather their readings, and the services that enrol and follow patients. Buyers are hospitals and clinics, home care and long-term care operators, and payers and care management organizations that fund programs for chronic and post-acute patients.

Between 2025 and 2034 the global remote patient monitoring market moves from USD 58 billion to USD 169 billion, compounding at 12.47% a year. Fifteen years are covered in all, taking in USD 29 billion in 2020, USD 50.6 billion in 2024, USD 66 billion in 2026 and USD 105.6 billion in 2030.

On the product type axis, growth rates run from 9.33% for Weight and Body Composition Scales up to 19.42% for Neurological Monitors. Cardiac Monitoring Devices carries the volume: USD 13.92 billion and 24% of revenue in 2025, USD 38.87 billion and 23% in 2034. The lines gaining share are Glucose Monitoring Devices, Respiratory Monitoring Devices, Fetal and Neonatal Monitors and Neurological Monitors. Vital Signs Monitors, Cardiac Monitoring Devices, Multi-parameter Monitors and Weight and Body Composition Scales lose share without losing revenue.

By component, Devices accounts for 52% of 2025 revenue at USD 30.16 billion, reaching USD 74.36 billion and 44% by 2034. Software and Platforms grows faster at 14.57% against 10.54%, moving from 30% of revenue to 35% by 2034. This axis divides the same revenue as the product type split instead of adding to it, so the two are read together and never summed.

USD 23.78 billion of 2025 revenue is generated in North America, 41% of the global total and the largest regional share; it reaches USD 59.99 billion by 2034. Europe is next at 24% and USD 13.92 billion, and Latin America last at 5.5%. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Behind these figures sit five regions, eight product type lines and ten segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 58 billion in 2025 to USD 169 billion in 2034, a compound annual rate of 12.47%, having reached USD 50.6 billion in 2024 from USD 29 billion in 2020.
• 24% of 2025 revenue sits in Cardiac Monitoring Devices (USD 13.92 billion) and it remains the largest product type line in 2034 at USD 38.87 billion and 23%.
• Neurological Monitors is the fastest-growing line at 19.42%, lifting its share from 4% in 2025 to 7% in 2034 and its revenue from USD 2.32 billion to USD 11.83 billion.
• Scenario range for 2034 runs from USD 140.5 billion in the bear case to USD 186 billion in the bull case, against a base-case USD 169 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 23.78 billion in 2025 (41% of the global total) and USD 59.99 billion by 2034, ahead of Europe at 24%.
• Within North America, the United States is the worked country example, at USD 21.4 billion in 2025; 90% of regional revenue in the base year, and USD 54 billion by 2034.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Three things move over 2026-2034, and they are worth separating: the product type mix, the regional balance, and the 12.47% compounding underneath both.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

The product type mix tilts toward Neurological Monitors. Between 2026 and 2034, 19.42% growth in Neurological Monitors against 9.33% in Weight and Body Composition Scales pulls the product type mix apart. Neurological Monitors takes its share of revenue from 4% to 7% while Weight and Body Composition Scales gives up ground, from 4.5% to 3.5%. Neither contracts: USD 2.32 billion becomes USD 11.83 billion, USD 2.61 billion becomes USD 5.92 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Asia Pacific gain regional share. Asia Pacific moves from 23% of revenue in 2025 to 31% in 2034, worth USD 13.34 billion rising to USD 52.39 billion. The offsetting side is North America at 41% moving to 35.5%, Europe at 24% moving to 22.5%, Latin America at 5.5% moving to 5.5%, Middle East and Africa at 6.5% moving to 5.5%, none of which contracts. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

A continuation, not an inflection. Fifteen years of revenue run USD 29 billion in 2020, USD 50.6 billion in 2024, USD 58 billion in 2025, USD 66 billion in 2026, USD 105.6 billion in 2030 and USD 169 billion in 2034. Against 14.87% through the historical period, the 12.47% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product type and regional axes, not by the headline rate.

Neurological Monitors adds the most incremental growth

Growth in the global remote patient monitoring market comes from three measurable sources over 2026-2034: the market's own compounding at 12.47%, the share gained by faster-growing product type lines, and expansion in the regions taking a larger part of global revenue.

Downside case: USD 140.5 billion by 2034, against USD 169 billion in the base case

Where the forecast could be beaten

Concentration on the product type axis

41% of the global remote patient monitoring market sits in North America in 2025, worth USD 23.78 billion on the way to USD 59.99 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Share settles at 35.5% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product type mix reported at global level applies here, with Cardiac Monitoring Devices the largest line at 24% of 2025 revenue and Neurological Monitors the fastest-growing at 19.42%. Per-axis and per-country detail for North America sits in the full report.

USD 21.4 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 54 billion by 2034. At 90% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 23.78 billion in 2025 and USD 59.99 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in the United States follows the product type mix reported at global level: Cardiac Monitoring Devices is the largest line at 24% of 2025 revenue, moving to 23% by 2034, while Neurological Monitors grows fastest at 19.42% and takes its share from 4% to 7%. Because the country carries 90% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-product type revenue for the United States appears on its own in the full report.

In the United States, remote patient monitoring devices fall under the Food and Drug Administration, which regulates them as medical devices. Most connected vital-sign sensors, such as blood pressure cuffs, pulse oximeters and glucose monitors, are Class II and reach the market through premarket notification, while some lower-risk products are exempt from that step. Suppliers must register their establishments, list their devices, follow the Quality System Regulation and report adverse events. Labelling must meet federal device labelling rules. Software and cybersecurity expectations apply to connected products, and patient data handling falls under HIPAA when a covered entity is involved. Reimbursement is set separately by Medicare and private payers.

Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education) are the suppliers covered in the United States. Volume sits in Cardiac Monitoring Devices at 24% of 2025 revenue; movement sits in Neurological Monitors at 19.42% growth. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 8.4% of regional revenue and 3.4% of the global total, worth USD 2 billion in 2025 and USD 5.4 billion by 2034.

USD 13.92 billion of 2025 revenue is generated in Europe, 24% of the global remote patient monitoring market and reaches USD 38.03 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 22.5%, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The product type mix reported at global level applies here, with Cardiac Monitoring Devices the largest line at 24% of 2025 revenue and Neurological Monitors the fastest-growing at 19.42%. Per-axis and per-country detail for Europe sits in the full report.

23% of Europe's base-year revenue comes from Germany; USD 3.2 billion, rising to USD 8.8 billion by 2034. Its 23% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 13.92 billion and USD 38.03 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Germany buys along the same lines as the market globally; Cardiac Monitoring Devices first at 24% of 2025 revenue and 23% in 2034, Neurological Monitors fastest at 19.42% on a share moving from 4% to 7%. With 23% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by product type for Germany is reported separately in the full report.

Germany applies the EU Medical Device Regulation to remote monitoring hardware and software. A supplier classifies each product by intended purpose, and most monitoring devices above the lowest risk class need conformity assessment by a notified body before the CE mark can be affixed. National oversight is handled by the Federal Institute for Drugs and Medical Devices, with state authorities supervising the market. Labelling must carry the CE mark, unique device identification and instructions in German. Manufacturers need a quality management system and post-market surveillance. Patient data is governed by the General Data Protection Regulation, and some apps can be prescribed through the national digital health applications pathway after review.

In Germany the field is Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Volume sits in Cardiac Monitoring Devices at 24% of 2025 revenue; movement sits in Neurological Monitors at 19.42% growth. The commercial size of that position is USD 13.92 billion in 2025, moving to USD 38.03 billion by 2034 across the forecast period.

5% of global revenue is generated in the United Kingdom; USD 2.9 billion in 2025, reaching USD 7.9 billion in 2034, and 20.8% of Europe.

Within Europe, France accounts for 14.4% of regional revenue and 3.4% of the global total, worth USD 2 billion in 2025 and USD 5.6 billion by 2034.

USD 13.34 billion of 2025 revenue is generated in Asia Pacific, 23% of the global remote patient monitoring market rising to USD 52.39 billion in 2034. Among the five regions it ranks third by revenue in both years.

Its share rises to 31% over the forecast period, on growth above the market's own 12.47%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the product type split tracks the global one; 24% of 2025 revenue in Cardiac Monitoring Devices, fastest growth of 19.42% in Neurological Monitors. Asia Pacific is reported axis by axis and country by country in the full study.

China is the largest market within Asia Pacific, generating USD 5 billion in 2025 and projected to reach USD 20.5 billion by 2034. 37.5% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 13.34 billion in 2025 and USD 52.39 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the product type mix reported at global level: Cardiac Monitoring Devices is the largest line at 24% of 2025 revenue, moving to 23% by 2034, while Neurological Monitors grows fastest at 19.42% and takes its share from 4% to 7%. With 37.5% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by product type for China is reported separately in the full report.

In China, remote patient monitoring devices are regulated by the National Medical Products Administration as medical devices. Suppliers classify each product into one of three risk classes. Lower-risk devices are filed, while higher-risk ones need registration with technical review and, in most cases, clinical evaluation and testing by an approved laboratory. Foreign manufacturers must appoint a local agent that holds the registration. Products must comply with mandatory national standards and carry Chinese-language labelling and instructions. Medical software has its own registration requirements. Handling of patient data is subject to the Personal Information Protection Law and the Data Security Law, including rules on moving data out of the country.

In China the field is Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Volume sits in Cardiac Monitoring Devices at 24% of 2025 revenue; movement sits in Neurological Monitors at 19.42% growth. A supplier weighted toward Asia Pacific is competing over a base of USD 13.34 billion in 2025, reaching USD 52.39 billion by 2034 on the trajectory this study models.

5% of global revenue is generated in Japan; USD 2.9 billion in 2025, reaching USD 8.2 billion in 2034, and 21.7% of Asia Pacific.

Within Asia Pacific, India accounts for 9.7% of regional revenue and 2.2% of the global total, worth USD 1.3 billion in 2025 and USD 6.4 billion by 2034.

Latin America holds 5.5% of the global remote patient monitoring market in 2025, worth USD 3.19 billion on the way to USD 9.3 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

5.5% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Cardiac Monitoring Devices largest at 24% of 2025 revenue, Neurological Monitors fastest at 19.42%. The full report breaks Latin America out along every axis and by country.

Brazil is the largest market within Latin America, generating USD 1.5 billion in 2025 and projected to reach USD 4.5 billion by 2034. At 47% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 3.19 billion to USD 9.3 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Brazil follows the product type mix reported at global level: Cardiac Monitoring Devices is the largest line at 24% of 2025 revenue, moving to 23% by 2034, while Neurological Monitors grows fastest at 19.42% and takes its share from 4% to 7%. Since 47% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-product type revenue for Brazil appears on its own in the full report.

Brazil regulates remote patient monitoring devices through ANVISA, the national health surveillance agency, which classifies medical devices into four risk classes. Lower-risk products are notified, while higher-risk ones require full registration. Foreign suppliers must work through a local registration holder and demonstrate good manufacturing practice, often through a certification audit. Electrical medical equipment generally needs conformity certification under the national INMETRO scheme. Labels and instructions must be in Portuguese. Software used for medical purposes is treated as a device and follows its own rules. Patient data is covered by the General Data Protection Law, and telehealth practice is overseen by the medical councils.

Competition in Brazil runs between the suppliers this study tracks: Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Cardiac Monitoring Devices, at 24% of 2025 revenue, is where the volume sits, and Neurological Monitors, growing at 19.42%, is where position changes hands over the forecast period. A supplier weighted toward Latin America is competing over a base of USD 3.19 billion in 2025, reaching USD 9.3 billion by 2034 on the trajectory this study models.

1.4% of global revenue is generated in Mexico; USD 0.8 billion in 2025, reaching USD 2.3 billion in 2034, and 25.1% of Latin America.

6.5% of the global remote patient monitoring market sits in Middle East and Africa in 2025, worth USD 3.77 billion rising to USD 9.29 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

Share settles at 5.5% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product type mix reported at global level applies here, with Cardiac Monitoring Devices the largest line at 24% of 2025 revenue and Neurological Monitors the fastest-growing at 19.42%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.8 billion in 2025 and projected to reach USD 2.2 billion by 2034. 21.2% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 3.77 billion to USD 9.29 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Saudi Arabia follows the product type mix reported at global level: Cardiac Monitoring Devices is the largest line at 24% of 2025 revenue, moving to 23% by 2034, while Neurological Monitors grows fastest at 19.42% and takes its share from 4% to 7%. Since 21.2% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-product type revenue for Saudi Arabia appears on its own in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority regulates remote patient monitoring devices under its medical devices framework. Suppliers must hold a Medical Device Marketing Authorization, and foreign manufacturers need a licensed local authorized representative. Devices are classified by risk, and the review draws on conformity evidence from recognised regulators, such as CE marking or approval in other major markets. Establishments must be licensed, and products must be listed before sale. Labelling must include Arabic information. Manufacturers are expected to run post-market surveillance and report incidents to the authority. Data protection falls under the Personal Data Protection Law, and the Ministry of Health sets telehealth practice requirements.

In Saudi Arabia the field is Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Cardiac Monitoring Devices, at 24% of 2025 revenue, is where the volume sits, and Neurological Monitors, growing at 19.42%, is where position changes hands over the forecast period. A supplier weighted toward Middle East and Africa is competing over a base of USD 3.77 billion in 2025 reaching USD 9.29 billion by 2034, 6.5% of global revenue at the start of that period.

Within Middle East and Africa, the United Arab Emirates accounts for 13.3% of regional revenue and 0.9% of the global total, worth USD 0.5 billion in 2025 and USD 1.4 billion by 2034.

0.7% of global revenue is generated in South Africa; USD 0.4 billion in 2025, reaching USD 0.9 billion in 2034, and 10.6% of Middle East and Africa.

Download a free sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product type, component, application, end user, connectivity technology, wearability, deployment mode, care model, patient age group, sales channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.